PCM
VVOS icon

Perkins Capital Management’s Vivos Therapeutics VVOS Stock Holding History

Perkins Capital Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-600
Closed -$3K – 96
2023
Q3 		$3K Sell
600
-220
-27% -$1.66K ﹤0.01% 98
2023
Q2 		$10K Sell
820
-80
-9% -$784 0.01% 95
2023
Q1 		$8K Sell
900
-1,180
-57% -$25.8K 0.01% 95
2022
Q4 		$21K Sell
2,080
-180
-8% -$2.63K 0.02% 97
2022
Q3 		$37K Sell
2,260
-4,292
-66% -$131K 0.04% 97
2022
Q2 		$211K Buy
6,552
+550
+9% +$22.8K 0.22% 80
2022
Q1 		$402K Buy
6,002
+560
+10% +$36.6K 0.33% 73
2021
Q4 		$306K Sell
5,442
-418
-7% -$33.7K 0.21% 83
2021
Q3 		$592K Sell
5,860
-640
-10% -$67.3K 0.37% 65
2021
Q2 		$804K Buy
+6,500
New +$1.06M 0.46% 58
2021
Q1 		– Sell
-800
Closed -$118K – 111
2020
Q4 		$118K Buy
+800
New +$146K 0.08% 91

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Perkins Capital Management's VVOS Position: Q4 2023 in Review

Perkins Capital Management sold out of Vivos Therapeutics (VVOS) in Q4 2023, closing a stake of 600 shares — an estimated $3K sold.

Perkins Capital Management first reported a position in VVOS in Q4 2020 and held it in 11 quarters. The position peaked at $804K in Q2 2021. 18 funds tracked by Wall St. Rank hold VVOS as of Q4 2023.

  • Perkins Capital Management reported no remaining Vivos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Perkins Capital Management sold 600 Vivos Therapeutics shares in Q4 2023, an estimated $3K.
  • Perkins Capital Management first reported a position in Vivos Therapeutics in Q4 2020 and held it in 11 quarters.
  • Perkins Capital Management's Vivos Therapeutics position peaked at $804K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2023.

Based on Perkins Capital Management's 13F filing for Q4 2023, filed 22 Jan 2024.